CN101406496A - Prescription for treating prostatitis and other reproductive system diseases of male - Google Patents
Prescription for treating prostatitis and other reproductive system diseases of male Download PDFInfo
- Publication number
- CN101406496A CN101406496A CNA2007101639351A CN200710163935A CN101406496A CN 101406496 A CN101406496 A CN 101406496A CN A2007101639351 A CNA2007101639351 A CN A2007101639351A CN 200710163935 A CN200710163935 A CN 200710163935A CN 101406496 A CN101406496 A CN 101406496A
- Authority
- CN
- China
- Prior art keywords
- mansostin
- prostatitis
- prescription
- treatment
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a formula for treating prostatitis and other male reproductive system diseases. The invention discloses a main compound extracted from mangosteen: Garcinia Mangostana, wherein alpha-mangostin is taken as a main effective constituent and mixed with various commonly used fillers in the medicine industry to prepare various appropriate preparation formulations including tablets, capsules, powder, and suppository; and the various preparation formulations can be used for preventing and treating male reproductive system inflammations such as prostatitis, orchitis, deferentitis and urethritis by means of oral taking or external application. The content of the alpha-mangostin in the product is between 3 and 99.8 percent; and the prepared product can relieve various inflammations, has the function of relieving pain to certain degree, and can be independently used or mixed with other natural substances for use.
Description
Technical field:
Prostatitis is the commonly encountered diseases of adult male, and general statistics accounting for 25%~30% of urology department outpatient service disease, and it can be completely without symptom, and is also can symptom obvious, protracted course of disease, even can cause and continue or the genito-urinary system of outbreak repeatedly infects.The most onsets of acute prostatitis are hurried, symptoms such as frequent micturition, urgent micturition, dysurea are arranged, adenitis is just so not simple before chronic, its symptom is a lot, mainly contain pain or discomfort, the time urinary tract infection symptom is arranged, serious prostatitis patient also has symptoms such as lassitude, fatigue and weakness, dizziness and tinnitus.
Current treatment at prostatitis and other disease in the male sexual system, non-steroidal commonly used (being non-steroid) anti-inflammatory agent (NSAID) all has side effect in various degree.The modal untoward reaction of NSAID has injury of gastrointestinal tract, hepatic and renal function injure, to the influence of blood system, central nervous system's symptom and allergy etc.Gastrointestinal reaction is the modal untoward reaction of NSAID, mainly shows as dyspepsia, feels sick vomiting, poor appetite, gastrointestinal mucosa damage, gastric duodenal ulcer, upper gastrointestinal hemorrhage and gastric perforation.The renal damage aspect, it is synthetic that most NSAIDs suppresses prostaglandin (PG), causes the kidney vasoconstriction, and renal perfusion can not be maintained, and the renal medulla ischemia causes renal damage.Renal damage shows as the minute lesion of acute renal failure, retention and dilutional hyponatremia, potassium mass formed by blood stasis, acute interstitial nephritis and renal medulla.Hepatic insufficiency the lighter raises for alanine aminotransferase due to the NSAID, and weight person is the hepatocellular degeneration necrosis.But the hepatic injury incidence rate is lower, and irreversible hepatic injury is rare, and old-age group, renal function injury, long-term heavy dose of application person can increase hepatic injury.NSAID commonly used much has pair central nervous system's reaction on the market, as ill effects such as dizziness, headache, drowsiness, mental disorders.Therefore, the present invention can not have side effects to human body again, for the patient provides a kind of sanatory safely and effectively product at effective treatment prostatitis and other disease in the male sexual system.
Background of invention:
The present invention is for containing Cortex Garciniae (mangosteen:Garcinia Mangostana) extract, it mainly contains effective constituent is alpha mansostin (alpha-mangostin), its content range is that the 2%-99.8% conduct of taking dose mainly contains effective constituent, cooperate suitable filler, make new product with anti-inflammatory analgesic.
Mansostin can be to extract from natural Cortex Garciniae shell or sarcocarp, can also be to produce by the method for chemosynthesis.
Compare with NSAID (non-steroidal anti-inflammatory drug) with existing steroid hormone class, the side effect of α-mansostin little (or avirulence), also non-stimulated to the intestines and stomach.α-mansostin is to extract from plant, and early is widely used in treating diarrhoea and malaria, antiulcer and leukemia and septicemia etc. in these plants traditional medicine abroad.Have physiologically active widely from the ketone compounds of plant extract, have the liver of separating poison, protect the liver, effect such as antiinflammatory, convulsion, inhibition monoamine oxidase, MAO.Although so multiple medicinal approach is arranged, in the ancient medical book of China, there is not write up.The range of application that α-mansostin and γ-mansostin have comprises and can be used as oral anti-inflammatory drug, and is all effectual to diseases such as prostatitis.Toxicological study experimental results show that in acute toxicity testing, and we are increased to the denseest level (people's dose 400 times) with dosage and still measure fatal dose (LD50) in the end, prove very safe; In addition, do not see the relevant report of α-mansostin and other medicines restriction or checking relation in five elements in the document so far yet in research.
Because Cortex Garciniae contains more α-mansostin, secondly is γ-mansostin, β-mansostin then has only on a small quantity, and latter's drug effect is average.The research that we did just concentrates on α-mansostin and γ-mansostin.The personal test of several aspiration patients by suffering from different syndromes, proof α-mansostin and γ-mansostin have good anti-inflammatory analgesic effect, and cell permeability is strong, porous is to the health different tissues, eliminate inflammation, and effective, required dosage is quite low, does not also find obvious toxic and side effects rapidly for effect.
Summary of the invention:
The prescription of multiple different proportion is contained in the present invention, male genetic inflammation such as treatment prostatitis, deferentitis, urethritis, and the pain at the position that reduces inflammation to a certain extent.The raw material that makes can be from whole Cortex Garciniae shell and sarcocarp, by water and ethanol method of purification, obtains the purification thing that contains (5-95%) xanthone (xanthones); These purification things include 2-75% α-mansostin [alpha (α)-mangostin] and can directly be used as and mainly contain effective constituent, cooperate other filler, make suitable dosage form, be used for the treatment of the multiple indication that the present invention declares: male genetic inflammation such as prostatitis, deferentitis, orchitis, urethritis, but be not limited to above-mentioned inflammation.Utilize the Cortex Garciniae extract further α-mansostin to be purified to more than 98%, as the concentrated dosage form of the above-mentioned sufferer of treatment, and spissated dosage form can reduce each dose.
Cortex Garciniae (mangosteen:Garcinia Mangostana) is a kind of common fruit plant, and its shell and sarcocarp have some drug effects, is widely used in antiulcer in south east asia, controls diarrhoea and germ-resistant conventional medicament.Wherein isolated α-, β-and γ-mansostin, and multiple different xanthone material (xanthones) is the chemical compound of its main biologically active, has in various degree antiinflammatory, sterilization, anti-amebic dysentery and antiulcer activity.We discover α-, β-and γ-mansostin, can suppress Cycloxygenase and sphingomyelinase, antagonism histamine receptor and 5-hydroxytryptamine receptor effectively and have antioxidation, pharmacological action such as antibiotic.We invent multiple different formulations, by zoopery and crowd's test, proof α-, β-and γ-mansostin the good cell permeability is arranged, this great discovery make α-, β-and γ-mansostin can become the various inflammation of treatment some existing antibiotic medicine (alclometasone diproionate and non-steroidal medicine) poor effect: comprise male genetic inflammation such as prostatitis, deferentitis, orchitis, urethritis.
The specific embodiment:
Multiple prescription is in proportion contained in the present invention, and effect is treatment prostatitis and other disease in the male sexual system.The employed effective constituent that mainly contains is alpha mansostin (alpha-mangostin), and its content range is the 2%-99.8% of taking dose, cooperates suitable filler, makes the new product with anti-inflammatory analgesic.The disease of main treatment is: prostatitis, deferentitis, orchitis, urethritis etc.Shen cellulose content is 3mg-300mg, and product can be made into the tablet of 50mg-1000mg or capsule or other dosage forms and conveniently takes.
Claims (9)
1. prescription for the treatment of prostatitis and other disease in the male sexual system, the present invention contains Cortex Garciniae (mangosteen:GarciniaMangostana) extract, it mainly contains effective constituent is alpha mansostin (alpha-mangostin), its content range is the 2%--99.8% of taking dose, and as mainly containing effective constituent, cooperate suitable filler, make new product with anti-inflammatory analgesic.
2. mansostin according to claim 1 can be to extract from natural Cortex Garciniae shell or sarcocarp, can also be to produce by the method for chemosynthesis.
3. mansostin according to claim 1 is the discomfort at a kind of scorching patient's in the prostatitis of can treating or releive relevant position, improves the patient simultaneously because of prostatitis cause urinating a kind of new product of puzzlement of aspect inconvenience.
According to claim 1 described in employed Cortex Garciniae extract, be equipped with suitable filler, make tablet or capsule is taken.And oral dose every day of manufactured goods is 50mg-500mg.
5. Shen cellulose content according to claim 1 is 3mg-300mg, and all the other are suitable filler.Product can be made into tablet or capsule or other dosage forms of 50mg-1000mg, conveniently takes.
6. suitable filler be can add according to the prescription in the claim 1 and edible solvent, stabilizing agent, lubricant, coating agent, antiseptic and emulsifying agent comprised.
7. contain mansostin 10-200mg in every of prescription according to claim 1 or each capsule, be used for the treatment of prostatitis.
8. according to the contained mansostin 10-200mg of the prescription in the claim 1, be used for the treatment of other reproductive system diseases, for example inflammation such as deferentitis, orchitis, urethritis and the pain that reduces inflammation and brought.
9. can be 5-50mg according to the contained mansostin of the prescription in the claim 1, be used for the treatment of urethritis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007101639351A CN101406496A (en) | 2007-10-12 | 2007-10-12 | Prescription for treating prostatitis and other reproductive system diseases of male |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007101639351A CN101406496A (en) | 2007-10-12 | 2007-10-12 | Prescription for treating prostatitis and other reproductive system diseases of male |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101406496A true CN101406496A (en) | 2009-04-15 |
Family
ID=40569841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101639351A Pending CN101406496A (en) | 2007-10-12 | 2007-10-12 | Prescription for treating prostatitis and other reproductive system diseases of male |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101406496A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110279689A (en) * | 2019-07-02 | 2019-09-27 | 浙江工业大学 | A kind of α-mangostin derivative is preparing the application in treatment-resistant prostatic hyperplasia agents |
WO2022239714A1 (en) * | 2021-05-13 | 2022-11-17 | 小林製薬株式会社 | Agent for preventing or improving nocturia, wakefulness after sleep onset, or frequent urination |
-
2007
- 2007-10-12 CN CNA2007101639351A patent/CN101406496A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110279689A (en) * | 2019-07-02 | 2019-09-27 | 浙江工业大学 | A kind of α-mangostin derivative is preparing the application in treatment-resistant prostatic hyperplasia agents |
CN110279689B (en) * | 2019-07-02 | 2021-05-11 | 浙江工业大学 | Application of alpha-mangostin derivative in preparation of anti-therapeutic prostatic hyperplasia drugs |
WO2022239714A1 (en) * | 2021-05-13 | 2022-11-17 | 小林製薬株式会社 | Agent for preventing or improving nocturia, wakefulness after sleep onset, or frequent urination |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101019984A (en) | Constipation treating Chinese medicine prepn | |
JP2011522844A (en) | Composition for reducing blood glucose level and use thereof | |
TWI654987B (en) | Combination of valerian root extract and lavender oil for the treatment of sleep disorders | |
RU2431494C1 (en) | Antiparasitic tea | |
KR100566542B1 (en) | A health food composition for prevention and treatment of allergic rhinitis and influenza and a method for preparation thereof | |
CN101406496A (en) | Prescription for treating prostatitis and other reproductive system diseases of male | |
CN105168500B (en) | It is a kind of to be used to treat pharmaceutical composition of dental ulcer of infant and preparation method thereof | |
WO2014154008A1 (en) | Purgative composition, preparation method therefor and application thereof | |
CN105169290A (en) | Traditional Chinese medicine composition for treating primary trigeminal neuralgia and application thereof | |
CN106420922B (en) | A kind of traditional Chinese medicine for external application for promoting postoperative gastroenteritic power and treating functional consitipation | |
JP7157253B2 (en) | Chinese herbal composition for enema constipation, its preparation method and its use | |
WO2009062374A1 (en) | The pharmaceutical use of liquiritigenin for preparing medicine for treating neurodegenerative diseases | |
CN100335083C (en) | Pile treating Chinese medicine prepn and its production process | |
CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
CN101804119B (en) | Traditional Chinese medicine preparation for treating thrombocytopenia and preparation method thereof | |
CN1954841B (en) | Medicine for treating chronic pharyngitis | |
JP4950551B2 (en) | Gastrointestinal mucosa protective agent | |
CN102940656B (en) | Medicine composition for treating benign prostatic hyperplasia | |
CN107260749B (en) | Drug, pharmaceutical composition and the application for treating sleep apnea syndrome | |
JPS6187621A (en) | Remedy for allergic rhinitis and allergic asthma | |
Verma et al. | Need of disintegrants and super-disintegrants in tablet formulations: a brief report | |
CN112439028A (en) | Lemon grass extract for treating hypertension and preparation method thereof | |
CN101569704A (en) | Traditional Chinese medicine for adjuvant therapy of hypnotic poisoning | |
WO2024077488A1 (en) | Relinqing granules having improved biological activity and disease treatment method | |
CN101721457A (en) | Medicine for treating oral ulcer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090415 |